InMed Pharmaceuticals Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
InMed Pharmaceuticals is a pharmaceutical company developing cannabinoid-based drug candidates, using proprietary manufacturing processes to produce rare cannabinoids for treating diseases such as skin conditions and neurological disorders.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC10% Owner | Buy | $1K | 1,086at $1.32 | Oct 19, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $1 | 1at $1.32 | Oct 16, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $750 | 564at $1.33 | Oct 13, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $11K | 8,021at $1.33 | Oct 14, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $1K | 984at $1.32 | Oct 15, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $7K | 5,601at $1.33 | Oct 6, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $4K | 3,046at $1.33 | Oct 7, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $3K | 2,256at $1.33 | Oct 8, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $24K | 18,182at $1.33 | Oct 5, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $11K | 8,307at $1.33 | Oct 2, 2026 |
| ADAR1 Capital Management, LLC10% Owner | Buy | $22K | 16,431at $1.33 | Oct 1, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable INM activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.